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PROGESTERONE VAGINAL RING  
BENEFICIAL ROLE IN BIRTH SPACING 
 
The Progesterone Vaginal Ring (PVR)  
is a vaginal ring which contains 
progesterone and can enhance the 
effect of breastfeeding on birth spacing.   
 
CONTRACEPTIVE EFFECT OF 
EXCLUSIVE BREASTFEEDING 
Postpartum family planning has received renewed focus with 
the issuance of new guidelines from the World Health 
Organization; some estimates of unmet need for 
contraception among women during the postpartum period 
are more than 60% in developing countries1,2.  
In this context, the lactational amenorrhea method (LAM) is 
recognized as an effective means of postponing the return to 
fertility in breastfeeding mothers as indicated by the onset of 
menstrual bleeding3-9. LAM is defined as a method that can 
effectively protect a woman from pregnancy if she meets all 
of the following three criteria: 1) Her period has not returned 
since her baby was born; 2) She is breastfeeding exclusively 
(fully) day and night, i.e. breast milk is the only source of 
water or nutrients during the first six months as long as the 
infant’s growth is adequate; 3) Her baby is less than six 
months old. As soon as the woman no longer meets one of 
these criteria, pregnancy rates increase and she needs to 
begin using another contraceptive method.  
Based on recent DHS surveys, however, a low proportion of 
women report compliance with the three criteria for the use 
of LAM in DHS surveys (usually less than 5% of breastfeeding 
women)10, although results from a large multicenter study on 
efficacy of LAM conducted in the early 1990s, suggest that 
deviation from specific use of each of the three criteria does 
not cause a significant upsurge in pregnancy rates11. It has 
been shown that the PVR as a new method of contraception 
during lactation, can provide additional protection to 
breastfeeding women who want to space their pregnancies 
for more than one year, but may not comply with the strict 
criteria of LAM. 
Lactational amenorrhea and its associated 
infertility have been shown to contribute to birth 
spacing, although variable effectiveness has 
been reported among different communities. In a 
population of highly motivated Chilean women 
(n=236) who breastfed up to 8 times per day, the 
risk of experiencing the first bleeding was 
reduced while fully breastfeeding with a high 
number of nursing episodes per day and night, 
but 25% and 50% of the women had started to 
cycle by the end of the fifth and eight postpartum 
month respectively3.  
After the first postpartum menses, the risk of 
pregnancy for breastfeeding women increases 
substantially3,12. The cumulative probability of 
pregnancy changes from 0.9% in amenorrheic 
women to 36% in cycling women at 6 months 
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 postpartum; and at 12 months, the pregnancy rate 
increases further from 17% (in amenorrheic women) to 
55% (in cycling women)12. 
Diaz et al4 demonstrated that the onset of bleeding before 
the sixth postpartum month, in fully breastfeeding women, 
predicts a higher risk of pregnancy.  The investigators 
calculated the probability of experiencing the first 
bleeding and the probability of pregnancy in 236 women 
who were fully breastfeeding and not using contraception 
and enrolled during the first month postpartum4-11. The 
cumulative probability of bleeding and of pregnancy was 
52% and 9.4% at day 180 postpartum, respectively. The 
risk of pregnancy was less than 2% in the subset of 
amenorrheic women4. These results confirmed that 
lactational amenorrhea provides effective contraceptive 
protection during the first six months postpartum. They 
also suggested that the first postpartum bleeding marks a 
discernible increase in the risk of pregnancy 4,12. 
After the sixth month postpartum, when breastfeeding will 
probably cease to be “full” or nearly full, it is increasingly 
likely that ovulation will precede the first vaginal bleed. 
Therefore, the protection against pregnancy that is 
afforded by breastfeeding decreases over time to levels 
lower than those of other family planning methods5. 
Based on these data, participants in a Bellagio consensus 
conference5 concluded that the maximum birth spacing 
effect of breastfeeding is achieved when a mother ‘fully” 
or nearly fully breastfeeds and remains amenorrheic. 
When these two conditions are fulfilled, breastfeeding 
provides more than 98% protection from pregnancy in the 
first six months5. 
CONTRACEPTIVE METHODS IN 
BREASTFEEDING WOMEN 
As a result of the growing urbanization and changing 
social norms about the role of women in developing 
countries, the duration of exclusive breastfeeding and its 
impact as a contraceptive strategy has been reduced. This 
situation has given rise to the need for a contraceptive 
method that could extend the infertile period following 
delivery, especially in countries where access to other 
contraceptives is limited and where longer duration of 
breastfeeding is a social norm and a major benefit to 
infant health. 
According to WHO Medical Eligibility Criteria (MEC), 
several methods are suitable for women who are 
breastfeeding and can be recommended13. Progestin-only 
pills (POP) have a longer half-life than progesterone, but 
need to be taken daily at approximately the same time. 
Long-acting methods such as the progestin implant or an 
intrauterine device (IUD) require access to trained health 
care providers for insertion and removal. The PVR was 
developed as a new user-controlled method that delivers 
a natural hormone for 3 consecutive months, hence not 
requiring daily attention by the user. Progesterone is 
metabolized quickly after ingestion in breast milk, limiting 
the steroid exposure to the infant. 
 
 
MECHANISM OF ACTION OF THE PVR 
The contraceptive mechanism of action of natural 
progesterone is similar to that of progestin-only pills, i.e. it 
suppresses ovulation, and reinforces the prolactin 
response to suckling9.  
Diaz et al9 explored the mechanism of action of progester-
one rings in lactating women by comparing ovarian function 
and prolactin levels between women who chose either a 
PVR or a Copper IUD at day 60 postpartum. Data were 
provided based on monthly follow up during one year of 
use. Frequency of breastfeeding and pregnancy rates in 
women who were relying only on lactational infertility were 
collected separately for comparative purposes9,12. 
The women (defined as fully or exclusively breast-feeding) 
were instructed not to give their babies any liquid or solid 
food or water during the first 6 months postpartum and to 
use the breast as the only source of fluids and nutrients, 
with the exception of vitamin drops. Milk supplements 
were indicated only when inadequate infant growth was 
diagnosed. Non-dairy meals were introduced after the 
sixth postpartum month.  
The endocrine profile during the first 8 months post-
partum was assessed in a sub-group of breastfeeding 
women including 36 PVR-treated women and 28 IUD-
users. Pre- and post-suckling prolactin (PRL) levels were 
measured at fortnightly intervals and E2 determinations 
and ovarian ultrasound were performed twice a week. 
Post-suckling PRL levels were significantly higher among 
PVR users (n=20) compared with IUD users (n=12);  
p=0.009. In PVR users, progesterone plasma levels 
ranged from 10 to 20 nmol/L, at lower levels than in a 
normal luteal phase. Similarly, E2 levels were lower, and 
follicular growth was arrested at earlier stages in the PVR 
vs. the IUD groups (Figures 1 & 2). 
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FIGURE 1 ESTRADIOL SERUM LEVELS BY 
MONTH OF EXPOSURE 
   
Mean of the Highest E2 Level in Lactating Women Treated with a Progesterone 
Vaginal Ring (PVR) or a Copper-T Device (IUD) p < 0.05 except in month 6 (M6). 
(Adapted from Diaz et al9) 
FIGURE 2 FOLLICLE DIAMETER AMONG USERS 
OF PVR OR IUD (3–8 MOS. POSTPARTUM) 
 
 
The authors concluded that progesterone increases the 
sensitivity of the breast-hypothalamic-pituitary system to 
suckling, as shown by the higher PRL levels in women using 
the PVR, and reinforces the mechanism of lactational 
infertility9. They also concluded that progesterone may 
affect the GnRH-releasing process independently of 
suckling9. These results, therefore, support the efficacy of 
the PVR in suppressing ovulation for a longer duration as 
compared with “untreated” women who demonstrate 
resumption of follicle growth and possible ovulation even 
when fully breastfeeding. 
CONTRACEPTIVE EFFICACY OF THE PVR 
In the study by Diaz et al9, pregnancy rates at the end of the 
year were 0.6% in PVR users and 0.7% in IUD users. In 
another study that included the population of 236 
breastfeeding only women, the pregnancy rates at one year 
were 39%12 (Table 1). 
 
TABLE 1 CONTRACEPTIVE EFFICACY OF THE 
PVR IN NURSING WOMEN  
 PVR Users T-CU Users 
Untreated 
Womenc 
Women 246a 442 226 
Pregnancies/WMb 1/2016 2/3461 50/1552 
Pearl Index 0.6 0.7 38.7 
Adapted from Diaz et al 9.  
aPVR 5 mg (n = 76), 10 mg (n = 109), or 15 mg (n = 61).   bWM= woman-
month; PVR and T-Cu were administered at day 60 ± 5 postpartum and the 
women were followed until month 14 postpartum. Untreated women were 
followed until month 12 postpartum.  cThe untreated group has been collected 
in another study12 and used in this table as historical comparison. 
 
 
All women in the PVR and IUD groups were amenorrheic 
at admission. By the end of month 8 postpartum, 78% 
of PVR users and 29% of T-Cu users remained so. The 
PVR group experienced a significantly lower risk of 
bleeding (p <0.0001) than did the IUD group.  
Massai et al14 also studied the contraceptive efficacy 
and safety of the PVR compared to the Copper T 380A 
IUD (T-Cu) in breastfeeding women enrolled at three 
Chilean clinics. A total of 285 volunteers chose to use 
the PVR and 262 women used the T-Cu. Ring replace-
ment was scheduled every 3 months. Volunteers con-
tinued in the study until weaning or completing the con-
tinuous use of four PVRs over one year. No pregnancies 
occurred in 2,320 and 2,183 woman-months of 
exposure with the PVR and the T-Cu, respectively. 
The mean duration of lactational amenorrhea was 361 
± 9 days in the PVR group and 198 ± 8 days in the T-Cu 
group (p<0.0001). The proportion of amenorrheic 
women at the 6th month postpartum was 87.4% among 
PVR users and 41.5% among T-Cu users (p = 0.0001). 
These percentages were three- and six fold higher in the 
PVR than in the T-Cu groups at months 9 and 12, 
respectively14.  The mean number of breastfeeding 
episodes was similar in both groups, decreasing from a 
mean of 10.1 episodes/day at month 3 to a mean of 5 
episodes/day at month 14 postpartum. Infant weights 
were similar in both groups14. 
In the Population Council’s large comparative 
multicentric trial that compared 802 women using the 
PVR and 734 women who received a copper-T 380A 
IUD, the 1-year pregnancy rate with the ring was at 1.5 
per 100 (431 women-years) and 0.5 per 100 in the 
copper-T 380A cohort (533 women-years). The 
percentage of women who were amenorrheic at 6 
months postpartum was 67.4% in the PVR group and 
43.7% among IUD users (p=0.0001); and at month 12, 
the rate of amenorrhea remained higher in the PVR 
group at 46.2% vs 16.1% in the IUD group (p=0.0001). 
There was no difference between groups in the mean 
number of breastfeeding episodes per day (d) which 
was around 9 meals/day at initiation and 6meals/d at 
12 months15. In addition, the weight of the infants did 
not differ between PVR or IUD users except at 12 
months and attributed to more supplements given in 
the IUD group15. 
Preliminary results from a recent study of PVR vs. 
IUD use conducted in India (2012-2015) provides 
similar results with respect to rates of lactational 
amenorrhea and average daily breastfeeding 
episodes over time. Pregnancy rates were identical 
(1 pregnancy in each group) as were infant growth 
patterns (ICMR & Population Council Internal Data – 
Protocol 418). 
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SUMMARY 
Results of clinical trials completed to date support the 
following conclusions regarding the role of breast-feeding 
and use of the PVR to promote child spacing: 
• Breastfeeding protects against pregnancy if a woman is 
fully breastfeeding and remains in amenorrhea; in this 
case her pregnancy risk will be about 0.9% at 6 months 
postpartum12. 
• When a first bleeding occurs before the 6th month, the 
risk of pregnancy increases to 9% and higher5,12. 
• The risk of experiencing the first bleeding is reduced while 
fully breastfeeding with a high number of nursing episodes 
per day and night, but nevertheless 25% and 50% of the 
women start to cycle by the end of the fifth and eight 
postpartum month, respectively3. 
• Using a Progesterone Vaginal Ring (PVR) prolongs 
amenorrhea in a higher proportion of women compared to 
women who are breastfeeding only. At 6 months, 87.4% of 
PVR users are amenorrheic versus 41.5% in IUD users14. 
• Users of a PVR show a higher suppression of ovarian 
follicles as compared with women using an IUD, with a 
majority of follicles at a diameter <10mm (82%), while IUD 
users show only 54% of follicles at <10mm. Follicles of 
>15mm were seen in 4% of PVR users and 23% of IUD 
users9. 
• In fully breastfeeding women, pregnancy rates at the end 
of one year are observed at < 1% in PVR users (treated) 
and at 39% in breastfeeding women not using any other 
contraception9,12. This low failure rate of the PVR appears 
to have been replicated in a recent study in India. 
Based on the review of the literature herein discussed, as 
well as preliminary findings from the recent study in India, it 
may be concluded that the PVR is effective in preventing an 
early return of follicle growth and ovulation, and preventing 
the return of cycling and fertility that may occur even in 
women who are fully breastfeeding9,12. A recent review of 
unmet need among postpartum women also suggests that in 
contexts where breastfeeding is common, counseling women 
about LAM and urging contraceptive adoption within six 
months of birth has programmatic rationale16.  
These conclusions support the position of offering the PVR to 
women who plan to breastfeed in the context of postpartum 
contraceptive counseling. In this regard, WHO has issued the 
following recommendation for use of the PVR:  
“Women who breastfeed and are four or more weeks 
postpartum can use the PVR without restrictions 
(MEC category 1)”. 
The Guideline Development Group advised that women who 
use the PVR must be actively breastfeeding (e.g. at least four 
breastfeeding episodes per day) to maintain the efficacy of 
the method13. 
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